BUSINESS

Nasdaq Companies Announce Dividends, Webcast, AI Progress

PUBLISHED May 5, 2026, 5:24 PM ET

Read, Watch or Listen

Media Bias Meter

Sources: 12

Center 100%

Sources: 12

United States: This week Nasdaq-listed firms issued corporate announcements signaling product advancement, shareholder returns and leadership change. On May 5, AIxCrypto reported Agentir in final testing and engagement at Bitcoin 2026; MarketWise declared a $0.25 regular and $0.20 special dividend. On May 6, PDS Biotech scheduled a May 13 investor webcast and ChronoScale named Cenly Chen CEO. The announcements include concrete dates and figures that shape near-term investor actions and operational plans: MarketWise set a record date of May 15 and payment date of June 25 for the $0.45 per Class A share distribution; PDS Biotech will host its financial and clinical update webcast on May 13 at 8:00 a.m. ET; ChronoScale’s CEO appointment is positioned to advance AI compute growth.

By Lauren Mitchell | JQJO News

Timeline of Events

May 5, 2026 — AIxCrypto publishes weekly update reporting Agentir in final testing and optimization.
May 5, 2026 — MarketWise Board declares $0.25 regular and $0.20 special dividends for Class A shares.
May 6, 2026 — PDS Biotechnology announces May 13, 2026 conference call and webcast for Q1 results.
May 6, 2026 — ChronoScale appoints Cenly Chen as Chief Executive Officer.
June 25, 2026 — Scheduled payment date for MarketWise dividend; record date May 15, 2026.

News Intelligence

These Nasdaq announcements can impact your investments. If you hold MarketWise Class A shares, expect a dividend payout on June
2
If you're eyeing AI or biotech sectors, watch AIxCrypto's Agentir progress and PDS Biotech's May 13 webcast.

Media Bias

Articles Published:: 12
Right Leaning:: 0
Left Leaning:: 0
Neutral:: 12

Who Benefited

Shareholders of MarketWise receive cash dividends; ChronoScale gains strategic leadership for AI compute growth; customers and infrastructure partners of AIxCrypto and PDS Biotech benefit from product progress, scheduled clinical and investor communications, and clarified corporate plans.

Who Impacted

No adverse impacts were disclosed in the releases; none of the articles reported layoffs, missed payments, regulatory penalties, or operational shutdowns.

Media Bias

Articles Published:: 12
Right Leaning:: 0
Left Leaning:: 0
Neutral:: 12
Distribution:: Left 0%, Center 100%, Right 0%

Who Benefited

Who Impacted

No adverse impacts were disclosed in the releases; none of the articles reported layoffs, missed payments, regulatory penalties, or operational shutdowns.